800 Scudders Mill Rd
Tel: (609) 987-5800
About Novo Nordisk
Novo Nordisk is the world's leading diabetes care company and the only company that provides a complete portfolio of insulin analog treatments and insulin delivery devices that respond to each stage of the diabetes life cycle. In addition, Novo Nordisk has a leading position in hemostasis management, growth hormone therapy and hormone therapy for women.
Novo Nordisk's ambition is to defeat diabetes, working as a catalyst to advance diabetes care through awareness, prevention, and education and to be at the forefront of research and development in other areas of healthcare where it can make a significant difference.
Triple Bottom Line
Novo Nordisk conducts its activities in a financially, environmentally, and socially responsible way as part of its underlying business principle, The Triple Bottom Line. This principle is the foundation of the Novo Nordisk Way of Management, which holds Novo Nordisk to the highest performance standards.
Novo Nordisk Highlights
• A heritage in diabetes care for more than 80 years • World's largest makers of insulin • More than 4,600 employees are engaged in research and development • In 2005, spent DKK 5,085 million in R & D • Operates manufacturing facilities in six nations, including the United States • Operates three research and development facilities worldwide (Denmark, US, China) • Rated as a healthcare leader on the global Dow Jones Sustainability World Index as well as the pan-European Dow Jones STOXX Sustainability Index (global recognition) • Named number one best place to work among large companies in NJ by NJBIZ magazine
• Global headquarters in Copenhagen, Denmark • US headquarters in Princeton, NJ • Employs an estimated 27,000 people in 81 countries • Markets its products in 179 countries • Employs 3900 people in the US • Insulin manufacturing facility in Clayton, NC
Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'.
Total sales in 2008 were: $8,935 million (DKK 45,553m) Net income-as reported in 2008: $1,892 million (DKK 9,645m) Earnings per share-as reported: $3.07(DKK 15.66) Dividends paid per share: $1.18(DKK 6.00)
History of Novo Nordisk
In the 1920s, two small Danish companies began producing insulin, which had just been discovered by a team of Canadian scientists. Nordisk Insulin laboratorium was founded in 1923.
A year later, Novo Terapeutisk Laboratorium was born, and began producing "Insulin Novo" and a special syringe. Over the decades, these two companies grew to be global leaders in insulin production. In January 1989, Novo and Nordisk decided to join forces to form a new company called Novo Nordisk A/S.
Please click here for clinical trial information.
FOLLOW NOVO NORDISK:
Tweets by Novo Nordisk
1073 articles with Novo Nordisk
Gilead Sciences, Inc. and Novo Nordisk A/S announced that the companies intend to collaborate on a clinical trial combining compounds from their respective pipelines in nonalcoholic steatohepatitis.
The companies will collaborate on a clinical trial to combine Novo Nordisk’s semaglutide and Gilead’s cilofexor and firsocostat for treatment of NASH.
The study, which uses data gathered from Great Places to Work, points to the company’s openness from its leadership and the treatment of its employees as the primary reason it took the top spot.
Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO - March 23, 2019
Oral semaglutide 7 mg and 14 mg demonstrated superior A1C and body weight reductions compared to Januvia®.
Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO
Oral semaglutide 7 mg and 14 mg demonstrated superior HbA1c and body weight reductions compared to Januvia®.
Novo Nordisk announced the results from its SUSTAIN 9 Phase IIIb trial. The trial compared Novo’s Ozempic (semaglutide) with an SGLT-2 inhibitor or placebo in adults with type 2 diabetes.
Novo Nordisk files for a label update for Fiasp® to the EMA and the FDA seeking approval for use in children and adolescents
Novo Nordisk announced that it recently submitted label updates to the European Medicines Agency and the US Food and Drug Administration for Fiasp® 100 u/mL, seeking approval for use as a new mealtime insulin for children and adolescents with type 1 diabetes.
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
On Tuesday, Novo Nordisk said the FDA approved its Biologics License Application for Esperoct (turoctocog alfa pegol) formerly known as N8-GP, for the treatment of children and adults with hemophilia A.
Abbott and Novo Nordisk Enter Partnership to Provide Integrated Digital Solution to People with Diabetes Using Insulin
Abbott (NYSE: ABT) and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLinkii mobile app and LibreViewiii cloud-based system).
2/13/2019The battle of the bulge is ongoing and it appears that Americans are losing, according to a report from the U.S. Centers for Disease Control and Prevention. The report shows that Americans are losing height and gaining girth.
The idea of swallowing a needle seems like a very bad idea. But a research team at MIT has developed a capsule about the size of a blueberry that holds a tiny needle that, after being swallowed, injects insulin into the stomach.
2/1/2019Many of the big biopharma companies reported fourth-quarter and year-end earnings this week. If there’s a theme among them, it seems lower earnings per share are forecast for the year.
Xultophy® now available in Canada to support improved glycemic control, an issue facing 50 per cent of Canadians with type 2 diabetes
An estimated 3.1 million Canadians live with type 2 diabetes, half of whom do not achieve adequate blood sugar control
In October, the Minnesota Attorney General filed a lawsuit against three of the biggest insulin manufacturers over price gouging claims. One month later the American Diabetes Association published recommendations and public policy solutions.
Novo Nordisk Investment Fund Backs Companies Developing Therapies Combatting Antimicrobial Resist...
1/21/2019Novo Nordisk’s investment arm, Novo Holdings, invested a little more than $20 million in four different companies over the course of 2018 through its REPAIR Impact Fund. That $165 million fund was established last year to support companies developing therapies to combat antimicrobial resistance.
It didn’t take long for the new leadership structure in the U.S. House of Representatives to take on the pharmaceutical industry. On Monday, the House Committee on Oversight and Reform launched an investigation into prescription drug pricing practices.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
Forbion Portfolio Company Staten Biotechnology Enters into a Collaboration with Novo Nordisk to Develop Novel Treatment for Dyslipidaemia
Forbion today announces that its portfolio company Staten Biotechnology B.V. and Novo Nordisk A/S have entered into a collaboration and exclusive option agreement to develop novel therapeutics for the treatment of hypertriglyceridaemia.
BioGeneration Ventures' portfolio company Staten Biotechnology announces collaboration with Novo Nordisk
BioGeneration Ventures is pleased to announce that its portfolio company Staten Biotechnology B.V. and Novo Nordisk A/S have entered into a collaboration and exclusive option agreement.